What would you consider to be an appropriate amount to spend on R&D then? Especially considering their cash.The POC research on the ovarian test is completed, the commercial assay is already under development. They’ve got another study due in December AND they managed to do another two studies on BC and OC In high risk women last quarter.
The next round of research and development is contingent on the completion of the commercial assay. That’s the priority because that will be the product that brings them the revenue that shareholders actually want.
Ann: Quarterly Activities Report and Cashflow, page-32
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
0.005(0.85%) |
Mkt cap ! $65.61M | |||
| Open | High | Low | Value | Volume |
| 59.5¢ | 59.5¢ | 59.5¢ | $3.887K | 6.533K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3467 | 59.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |